Anti-PD-L1 checkpoint inhibitors: Decoding the mystery

July 24, 2019 | City of Hope

An study conducted by Michael Caligiuri, M.D., and Jianhua Yu, Ph.D., unveiled why anti-PD-L1 monoclonal antibodies (mAb) are still effective in fighting tumors that lack PD-L1 receptors on their cells.

Continue Reading

CAR T Cell Therapy in Cancer Forum

November 27, 2018 | City of Hope

CAR T cell therapy is one of the most promising new approaches for treating cancer today. Come spend a day learning more about CAR T cell therapy from City of Hope’s resident experts to better understand what is now at the forefront of oncology treatment.

Renowned Cancer Researcher Named President of City of Hope National Medical Center and Physician-in-Chief of City of Hope

November 28, 2017 | City of Hope

Michael A. Caligiuri, M.D., a world-renowned cancer researcher, has been named president of City of Hope National Medical Center and physician-in-chief of City of Hope.

Get Access Now: Car t Cell Therapy for Aggressive Non-Hodgkin Lymphoma

November 17, 2017 | City of Hope

City of Hope is now offering the first-ever FDA-approved CAR T cell therapy for adult patients with certain types of large B-cell lymphoma who have not responded to or who have relapsed after at least two other kinds of treatment.

Researchers achieve remission using CAR T Cell therapy for aggressive brain tumors

February 15, 2017 | Denise Heady

City of Hope case study published in the New England Journal of Medicine reported treatment with reengineered CAR T cells dramatically improved quality of life for patient with recurrent glioblastoma.

Using CAR T cell immunotherapy to target glioblastomas

December 14, 2016 | Denise Heady

One of but a few centers in the United States offering human studies in CAR–T cell therapy, City of Hope is the only center investigating CAR T cells in injection form administered directly to brain tumors.

Clinical Trials Take CAR T Therapy to Patients Who Need It

December 14, 2016 | City of Hope

City of Hope has the clinical and scientific expertise to house the entire clinical trial process on its campus — including collecting the cells, manufacturing the lentivirus, modifying and replicating the cells and reinfusing them.

Study finds Triplex vaccine safe for use in healthy populations

December 14, 2016 | City of Hope

Data published in Blood supports ongoing phase 2 trial of Triplex in allogeneic hematopoietic stem cell transplant recipients.

Alliance Brings More Firepower to the Fight Against Cancer

December 1, 2016 | City of Hope

City of Hope joins forces with the Translational Genomics Research Institute (TGen) to accelerate the speed with which scientists and clinicians can convert research discoveries into cures.